5 research outputs found
Recommended from our members
Commissioning of the superconducting ECR ion source VENUS
VENUS (Versatile ECR ion source for NUclear Science) is a next generation superconducting ECR ion source, designed to produce high current, high charge state ions for the 88-Inch Cyclotron at the Lawrence Berkeley National Laboratory. VENUS also serves as the prototype ion source for the RIA (Rare Isotope Accelerator) front end. The magnetic confinement configuration consists of three superconducting axial coils and six superconducting radial coils in a sextupole configuration. The nominal design fields of the axial magnets are 4T at injection and 3T at extraction; the nominal radial design field strength at the plasma chamber wall is 2T, making VENUS the world most powerful ECR plasma confinement structure. The magnetic field strength has been designed for optimum operation at 28 GHz. The four-year VENUS project has recently achieved two major milestones: The first plasma was ignited in June, the first mass-analyzed high charge state ion beam was extracted in September of 2002. The pa per describes the ongoing commissioning. Initial results including first emittance measurements are presented
Recommended from our members
Commissioning of the superconducting ECR ion source VENUS at 18 GHz
During the last year, the VENUS ECR ion source was commissioned at 18 GHz and preparations for 28 GHz operation are now underway. During the commissioning phase with 18 GHz, tests with various gases and metals have been performed with up to 2000 W RF power. The ion source performance is very promising [1,2]. VENUS (Versatile ECR ion source for Nuclear Science) is a next generation superconducting ECR ion source, designed to produce high current, high charge state ions for the 88-Inch Cyclotron at the Lawrence Berkeley National Laboratory. VENUS also serves as the prototype ion source for the RIA (Rare Isotope Accelerator) front end. The goal of the VENUS ECR ion source project as the RIA R&D injector is the production of 240e{micro}A of U{sup 30+}, a high current medium charge state beam. On the other hand, as an injector ion source for the 88-Inch Cyclotron the design objective is the production of 5e{micro}A of U{sup 48+}, a low current, very high charge state beam. To meet these ambitious goals, VENUS has been designed for optimum operation at 28 GHz. This frequency choice has several design consequences. To achieve the required magnetic confinement, superconducting magnets have to be used. The size of the superconducting magnet structure implies a relatively large plasma volume. Consequently, high power microwave coupling becomes necessary to achieve sufficient plasma heating power densities. The 28 GHz power supply has been delivered in April 2004
Recommended from our members
Development of ECR ion source and LEBT technology for RIA
The Rare Isotope Accelerator (RIA) Linac driver requires a great variety of high charge state ion beams with up to a magnitude higher intensity than currently achievable for the heaviest masses. The goal of the RIA injector R&D program for VENUS is the reliable production of intense medium charge state ion beams, e.g., 8 puA (particle mu A) of U29+. Therefore, the superconducting ECR ion source VENUS has been designed from the beginning for optimum operation at 28 GHz at high power (10 kW). In addition, a high intensity Low Energy Beam Transport, LEBT, that was developed to analyze and transport these multiply-charged, space charge dominated beams. During the last year VENUS was commissioned at 18 GHz and preparations for 28 GHz operation continued. Tests with various gases and recently metals have been performed with up to 2000 W of 18 GHz RF power. Promising performance has been measured in those preliminary beam tests. For example, 180 p mu A of O6+, 15 p mu A of Ar12+, 7.5 puA of Xe20+ and 4puA of Bi24+ were produced in the early commissioning phase, ranking VENUS among the currently highest performance 18 GHz ECR ion sources. In FY04 a 10 kW 28 gyrotron system will be added, which will enable VENUS to reach full performance. The emittance of the beams produced at 18 GHz was measured with a two axis emittance scanner developed with earlier RIA R&D funds
Recommended from our members
Test Performance Characteristics of the AIR, GAD-7 and HADS-Anxiety Screening Questionnaires for Anxiety in Chronic Obstructive Pulmonary Disease
Rationale: Anxiety is a common comorbidity of chronic obstructive pulmonary disease (COPD) that is associated with higher morbidity and mortality. We evaluated three anxiety screening questionnaires: the Generalized Anxiety Disorder 7-Item Scale (GAD-7), the Hospital Anxiety and Depression Scale Anxiety subscale (HADS-A), and the Anxiety Inventory for Respiratory Disease (AIR).Objectives: To evaluate and compare the test performance characteristics of three anxiety screening questionnaires, using the Mini-International Neuropsychiatric Interview (MINI), version 7.0, as the "gold standard."Methods: Individuals with COPD were recruited at 16 centers. The MINI and questionnaires were administered by trained research coordinators at an in-person visit and readministered by telephone 2-4 weeks later. A composite score for the presence of any Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) anxiety disorder was computed, based on the MINI as the gold standard, compared with a participant screening positive on self-report measures for these analyses.Results: Two hundred and twenty eligible individuals with COPD were enrolled; 219 completed the study. Eleven percent were identified as having a DSM-V anxiety disorder, based on the MINI. Elevated anxiety symptoms based on questionnaires were 38% for the AIR, 30% for the GAD-7, and 20% for the HADS-A. Area under the receiver operating characteristic curve (AUC) was highest for the GAD-7 (0.78; 95% confidence interval [CI], 0.69-0.87), followed by the HADS-A (0.74; 95% CI, 0.64-0.84) and the AIR (0.66; 95% CI, 0.56-0.76). The AUC for the GAD-7 was significantly greater than for the AIR (P = 0.014). Sensitivity was not statistically different among the questionnaires: 77% for the GAD-7, 63% for the HADS-A, and 66% for the AIR. The HADS-A had the highest specificity, 85%, which was significantly higher than that of the GAD-7 (77%; P < 0.001) and the AIR (65%; P < 0.001); GAD-7 specificity was higher than AIR specificity (P < 0.001).Conclusions: Symptoms of anxiety among patients with COPD as identified by screening questionnaires were common and significantly higher than the prevalence of anxiety disorder meeting DSM-V criteria. The GAD-7, the HADS-A and the AIR questionnaires had fair to moderate psychometric properties as screening tools for anxiety in individuals with COPD, indicating the need for improved measures for this patient population